.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SURPASS-2 directly compared once-weekly tirzepatide with semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. Across the studied tirzepatide doses, reductions in HbA1c and body weight were greater than with semaglutide. Gastrointestinal adverse events were the most common treatment-related effects and were generally mild to moderate. The trial is highly relevant to current diabetes practice because dual GIP/GLP-1 receptor agonism has expanded the therapeutic conversation beyond glucose lowering alone. For clinicians, the key point is not that one drug is universally superior, but that treatment selection can increasingly be personalized according to glycemic burden, weight goals, cardiovascular and kidney risk, injection burden, cost and patient preference. The study also illustrates the importance of interpreting head-to-head comparisons in the context of the doses used and the population studied. In routine practice, careful dose escalation and counseling around gastrointestinal effects can improve persistence. SURPASS-2 therefore fits naturally into discussions about moving from “HbA1c control” toward broader metabolic risk reduction.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SURPASS-2 directly compared once-weekly tirzepatide with semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. Across the studied tirzepatide doses, reductions in HbA1c and body weight were greater than with semaglutide. Gastrointestinal adverse events were the most common treatment-related effects and were generally mild to moderate. The trial is highly relevant to current diabetes practice because dual GIP/GLP-1 receptor agonism has expanded the therapeutic conversation beyond glucose lowering alone. For clinicians, the key point is not that one drug is universally superior, but that treatment selection can increasingly be personalized according to glycemic burden, weight goals, cardiovascular and kidney risk, injection burden, cost and patient preference. The study also illustrates the importance of interpreting head-to-head comparisons in the context of the doses used and the population studied. In routine practice, careful dose escalation and counseling around gastrointestinal effects can improve persistence. SURPASS-2 therefore fits naturally into discussions about moving from “HbA1c control” toward broader metabolic risk reduction.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
